Shuttle Pharmaceuticals Holdings has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule. Nasdaq sent notice to the Company that it had regained compliance as of August 27, 2024, after it traded above $1.00 per share for ten consecutive trading days.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharmaceuticals receives noncompliance notification from Nasdaq
- Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
- Shuttle Pharmaceuticals opens enrollment in Ropidoxuridine trial
- Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
- Shuttle Pharmaceuticals Holdings Inc trading halted, news pending